Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3580057 | 0.82 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL3579727 | 0.82 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL4102061 | 0.82 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL2065859 | 0.80 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2065863 | 0.80 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL901923 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL25614276 | 0.79 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3577487 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3579666 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23701365 | 0.76 | AKR1C3 (0.44) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700639-A1 | Selective ligands for the neuronal nicotinic receptors and uses thereof | Abbvie Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8648084-B2 | Selective substituted pyrazine ligands for neuronal nicotinic receptors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | ABBVIE INC. | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190692-A1 | SELECTIVE SUBSTITUTED PYRIDINE LIGANDS FOR NEURONAL NICOTINIC RECEPTORS | CHRNA4, CHRNB4, CHRNA2 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.